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Abstract
 
CD1d-restricted V
 
 
 
24-J
 
 
 
18–invariant natural killer T cells (iNKTs) are potentially important
in tumor immunity. However, little is known about their localization to tumors. We analyzed
98 untreated primary neuroblastomas from patients with metastatic disease (stage 4) for tumor-
infiltrating iNKTs using TaqMan
 
®
 
 reverse transcription polymerase chain reaction and immun-
ofluorescent microscopy. 52 tumors (53%) contained iNKTs, and oligonucleotide microarray
analysis of the iNKT
 
 
 
 and iNKT
 
 
 
 tumors revealed that the former expressed higher levels of
CCL2/MCP-1, CXCL12/SDF-1, CCL5/RANTES, and CCL21/SLC. Eight tested neuro-
blastoma cell lines secreted a range of CCL2 (0–21.6 ng/ml), little CXCL12 (
 
 
 
0.1 ng/ml), and
no detectable CCL5 or CCL21. CCR2, the receptor for CCL2, was more frequently expressed by
iNKT compared with natural killer and T cells from blood (P 
 
  
 
0.001). Supernatants of neu-
roblastoma cell lines that produced CCL2 induced in vitro migration of iNKTs from blood of
patients and normal adults; this was abrogated by an anti-CCL2 monoclonal antibody. CCL2
expression by tumors was found to inversely correlate with MYCN proto-oncogene amplification
and expression (r 
 
 
 
 0.5, P 
 
 
 
 0.001), and MYCN-high/CCL2-low expression accurately pre-
dicted the absence of iNKTs (P 
 
  
 
0.001). In summary, iNKTs migrate toward neuroblastoma
cells in a CCL2-dependent manner, preferentially infiltrating MYCN nonamplified tumors
that express CCL2.
Key words: lymphocytes • tumor-inﬁltrating • T lymphocyte subsets • cell movement • 
immunologic surveillance
 
Introduction
 
V
 
 
 
24-J
 
 
 
18–invariant natural killer T cells (iNKTs) are an
evolutionarily conserved subset of T cells that depend on
CD1d for their development and that specifically recognize
 
 
 
-galactosylceramide (
 
 
 
GalCer) bound to CD1d. iNKTs
respond to specific stimulation by rapidly producing a spec-
trum of cytokines including IL-13 and IL-4 (type 2) and
IFN-
 
 
 
 (type 1; references 1, 2). iNKTs may be a part of the
innate immune reaction and promote initiation of acquired
immune responses (3).
iNKTs are potentially important in tumor immunity (4, 5).
They can naturally prevent formation of chemical carcino-
gen–induced tumors in mice (6, 7) and eradicate estab-
lished tumors in mice after 
 
 
 
GalCer injection by inducing
NK cells to produce IL-12 and IFN-
 
 
 
 (8). However, a
murine model of tumor growth-regression-recurrence sug-
gested that, without exogenous stimulation, iNKTs may
prevent CTL-mediated tumor eradication by producing
IL-13 (9, 10). Recent phase I clinical trials with 
 
 
 
GalCer-
pulsed dendritic cells demonstrated that in vivo stimulation
of iNKTs leads to modulation of NK, T, and B cell numbers
and increased serum IFN-
 
 
 
 (11, 12). Presumably, iNKT
cell effector functions occur within the tumor microenvi-
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Abbreviations used in this paper:
 
 
 
 
 
GalCer, 
 
 
 
-galactosylceramide; DAPI,
4
 
 
 
,6-diamidine-2
 
 
 
-phenylindole dihydrochloride; FU, fluorescence units;
IHC, immunohistochemistry; iNKT, V
 
 
 
24-J
 
 
 
18–invariant natural killer
T cell; TEM, transendothelial migration. 
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ronment, but little is known about their infiltration into tu-
mors. Recent studies of human myeloma, lung adenocarci-
nomas, and lung squamous cell carcinomas demonstrated
iNKTs in the tumor microenvironment (13, 14), but the
mechanisms of their localization were not investigated.
Human iNKTs express chemokine receptors that may en-
able their migration into extra lymphoid tissues (15); there-
fore, we hypothesized that they infiltrate tumors in re-
sponse to one or more chemokines.
Similar to many types of cancer, lymphocytes have been
detected in neuroblastomas from patients (16), and most are
T cells with varying proportions of CD4
 
 
 
, CD8
 
 
 
, and dou-
ble negative subsets (17). We determined if some of these
infiltrating T cells were iNKTs and if their localization was
associated with intratumor expression of chemokines. 42%
of neuroblastomas from patients with metastatic disease con-
tain iNKTs, and their presence was highly correlated with
expression of the chemokine CCL2. Of note, tumors with
genomic amplification and high expression of the MYCN
oncogene had low expression of CCL2 and little or no
iNKT infiltration. Last, we show that human neuroblastoma
cell lines can secrete CCL2, which mediates transendothelial
migration (TEM) of fresh blood iNKTs in vitro.
 
Materials and Methods
 
Neuroblastomas, Blood Specimens, and Cell Lines. 
 
98 primary
untreated stage 4 neuroblastomas were analyzed. 79 tumors,
which were diagnosed after 1 yr of age, were obtained from pa-
tients enrolled in Children’s Cancer Group study CCG-3891 for
high-risk neuroblastoma. CCG-3891 used a single induction
regimen consisting of cisplatin, doxorubicin, etoposide, and cy-
clophosphamide as well as surgery. This was followed by ran-
domized assignment to either further chemotherapy (ifosfamide,
doxorubicin, etoposide, and cisplatin) or myeloablative chemora-
diotherapy (carboplatin, etoposide, melphalan, and total body ir-
radiation) supported by purged autologous bone marrow trans-
plantation. Finally, patients were randomized to receive 13-cis
retinoic acid beginning 100 d after autologous bone marrow
transplantation or no further treatment (18). 19 tumors were ob-
tained from children who were diagnosed before 1 yr of age and
who were enrolled in protocol CCG-3881 for intermediate-risk
neuroblastoma. After surgery at diagnosis, these patients received
cyclophosphamide, cisplatin, etoposide, and doxorubicin at 28-d
intervals for 9 mo.
Specimens were snap frozen within 2 h of surgery in foil or af-
ter embedding in OCT compound and were maintained at
 
 
 
80
 
 
 
C. PBMCs were isolated from freshly obtained blood from
normal adult donors or newly diagnosed patients with stage 4,
high-risk neuroblastoma enrolled in Children’s Oncology Group
study A3973. LA-N-1 and LA-N-2 neuroblastoma cell lines
were established in our laboratory (19), and CHLA-15, CHLA-
20, SMS-KAN, SMS-KANR, SMS-KCN, and SMS-KCNR
neuroblastoma cell lines were provided by C.P. Reynolds (Chil-
drens Hospital, Los Angeles, CA). All cell lines have been iden-
tity typed with the AmpliType assay (Applied Biosystems). iNKT
cell lines (
 
 
 
99% CD1d/
 
 
 
GalCer-reactive) were established as
described previously (20). Informed consent was obtained in ac-
cordance with institutional review board policies and procedures
for research dealing with tumors and blood specimens.
 
Real-Time RT-PCR. 
 
TaqMan
 
®
 
 real-time RT-PCR was used
to detect V
 
 
 
24-J
 
 
 
18 RNA with the Sequence Detection System
(ABI Prism model 7700; Applied Biosystems). The probe spanned
the junction of V
 
 
 
24-J
 
 
 
18 TCR. The forward primer was 5
 
 
 
-
CCTCCCAGCTCAGCGATTC-3
 
 
 
, and the reverse primer was
5
 
 
 
-TATAGCCTCCCCAGGGTTGA-3
 
 
 
. The probe was FAM-
5
 
 
 
-CCTCCTACATCTGTGTGGTGAGCGACA-3
 
 
 
-TAMTph.
The probe design was based on the sequence from GenBank/
EMBL/DDBJ accession nos. HSTCRA002 for V
 
 
 
24 and S63026
for J
 
 
 
18, respectively. The probe for CCL2 was FAM-5
 
 
 
-CCAAG-
GAGATCTGTGCTGACCCCAA-3
 
 
 
-TAMTph, and the primers
were designed between exon 2 and exon 3. The forward primer
was 5
 
 
 
-GAAGAATCACCAGCAGCAAGTGT-3
 
 
 
, and the re-
verse primer was 5
 
 
 
-TGGAATCCTGAACCCACTTCTG-3
 
 
 
. The
probe for MYCN was FAM-5
 
 
 
-AGAAGCGGCGTTCCTCCT-
CCAACA-3
 
 
 
-TAMTph, and the primers were 5
 
 
 
-GAAGAAATC-
GACGTGGTCACTG-3
 
 
 
 (forward) and 5
 
 
 
-GGTGAATGTGGT-
GACAGCCTT-3
 
 
 
 (reverse). The probe and primer designs were
based on the sequence from GenBank/EMBL/DDBJ accession no.
HSMCP-1. All probes and primers were designed using a software
program (Primer Express V1.5; Applied Biosystems) and were syn-
thesized by Integrated DNA Technologies.
 
Oligonucleotide Array Expression Analysis. 
 
Total RNA was
precipitated from samples using TRIzol
 
®
 
 (Invitrogen) and further
purified with the RNeasy Mini kit (QIAGEN). Double-stranded
cDNA was synthesized from total RNA using HPLC purified
T7-(dT) primer (5
 
 
 
-GGCCAGTGAATTGTAATACGACT-
CACTATAGGGAGGCGG-(dT)
 
24
 
-3
 
 
 
 (Genset Co.) and purified
using phase lock gels, phenol/chloroform extraction, and ethanol
precipitation. Biotin-labeled cRNA was synthesized from cDNA
(in vitro transcription) using the ENZO Bioarray High Yield
RNA Transcript Labeling kit (Affymetrix) and purified with
RNeasy columns (QIAGEN) and ethanol precipitation. After
quantification with a spectrophotometer, cRNA was fragmented
and hybridized to Affymetrix U95Av2 arrays (79 patients, diag-
nosed after 1 yr of age) or U133A and
 
 
 
U133B arrays (19 patients,
diagnosed before 1 yr of age). Arrays were washed and scanned
according to the manufacturer’s instructions (Affymetrix). Data
from Affymetrix .cel files were preprocessed using dChip
 
®
 
 soft-
ware to normalize arrays, calculate model-based expression val-
ues, and identify probe and array outliers (21). Genetrix
 
®
 
 soft-
ware (provided by J. Buckley, University of Southern California,
Los Angeles, CA) was used to obtain gene expression levels,
which are termed fluorescence units (FU).
 
MYCN Genomic Analysis. 
 
MYCN was analyzed to identify
tumors with genomic amplification by Southern blot, PCR, and/
or immunohistochemistry (IHC) as described previously (22–24).
 
ELISA. 
 
Kits for CCL2, CCL5, CCL21, and CXCL12 were
purchased from R&D Systems, and chemokine concentration
was determined in neuroblastoma cell supernatants according to
the manufacturer’s instructions.
 
Flow Cytometry. 
 
To analyze CCR2 expression by blood
iNKTs, PBMCs were sequentially stained with anti-CCR2
48607.121 mAb (R&D Systems), anti–mouse IgG-biotin and
Cy-Chrome-streptavidin plus FITC anti-V
 
 
 
11 (Beckman Coul-
ter) and PE anti–V
 
 
 
24-J
 
 
 
18 6B11 (25). T and NK cells were an-
alyzed with FITC anti-CD3 UCHT1 and PE anti-CD56 B159
(BD Biosciences). Isotype-matching MOPC-21 mAb was used as
control (BD Biosciences). Samples were analyzed with a EPICS
 
®
 
Elite flow cytometer (Beckman Coulter). Data were analyzed us-
ing EXPO™ 32 Analysis software (Beckman Coulter).
 
Immunofluorescence Microscopy and IHC. 
 
Frozen 6-
 
 
 
m sec-
tions were brought to room temperature, fixed in acetone (10 
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min), and treated with 5% goat serum supplemented with 2.5%
BSA for 20 min. Sections were incubated with Alexa Fluor
 
®
 
 488
anti-CD3 289-13801 mAb (Molecular Probes) for 1 h at room
temperature. The sections were washed with PBS containing
0.5% BSA and counterstained with 4
 
 
 
,6-diamidine-2
 
 
 
-phenylin-
dole dihydrochloride (DAPI; Vector Laboratories). Where indi-
cated, tissue sections were sequentially stained with anti–V
 
 
 
24-
J
 
 
 
18 6B11 mAb (26, 27) followed by Cy™3-anti–mouse IgG
(Jackson ImmunoResearch Laboratories) and Alexa Fluor
 
®
 
 488-
anti-CD3 mAb. Digital images of fluorescent microscope fields of
tumor sections were acquired with a HCX Plan Apochromat
40
 
 
 
/1.25NA oil immersion objective lens with 1.6
 
 
 
 optivar on
a DM RXA microscope (Leica), Lambda LS175 Xenon arc lamp
(Sutter Instrument Co.), using HQ Cy3, HQ fluorescein, and
DAPI filter sets (Chroma Technology Corp.) with a SKY™ SD-
300/VDS1300 spectral imager and EasyFish software (Applied
Spectral Imaging). All nucleated (DAPI
 
 
 
) and T cells (CD3
 
 
 
)
were counted in four randomly selected fields and the percentage
of T cells was calculated as CD3
 
 
 
/DAPI
 
 
 
 
 
 
 
 100. For immuno-
histochemical detection of CCL2, we used goat anti–human
CCL2 Ab followed by Cell and Tissue Staining Kit (R&D Sys-
tems). IHC for CD1d was performed using 42.1 anti-hCD1d
mAb (provided by S. Porcelli, Albert Einstein College of Medi-
cine, Bronx, NY).
 
TEM Assay. 
 
Polycarbonate transwell filters with 5-
 
 
 
m pore
size (Costar Corning) were precoated with human umbilical
vein endothelial cells (American Type Culture Collection) using
F-12K medium (American Type Culture Collection) supplemented
with 10% FCS and 0.03 mg/ml endothelial cell growth supple-
ment (BD Biosciences). After rinsing once in RPMI 1640, tran-
swell inserts were transferred to new wells (lower chambers) con-
taining 600 
 
 
 
l RPMI 1640 with 5 mg/ml human serum albumin.
Recombinant chemokines or supernatants from neuroblastoma
cell lines were added to the lower chambers. An iNKT cell line
(20) or PBMCs depleted of monocytes were added to the upper
chamber (10
 
6
 
 cells in 100 
 
 
 
l), and the transwell chambers were
incubated at 37
 
 
 
C in 5% CO
 
2
 
. After 4 h, initial input cells (from a
nonpermeable well) and migrated cells from the lower chambers
were stained with fluorochrome-conjugated mAbs (see flow cy-
tometry section). iNKTs were identified using FITC anti-V
 
 
 
11
C21 mAb (Beckman Coulter) with PE anti-V
 
 
 
24-J
 
 
 
18 6B11.
After suspension in TruCOUNT™ tubes (Becton Dickinson),
multicolor immunofluorescence was analyzed by flow cytometry
to determine relative and absolute numbers of cells in subpopula-
tions of interest. The percent migration for each subset was calcu-
lated as migrated cells/input cells 
 
  
 
100. Specific migration was
calculated by subtracting migration to control medium from mi-
gration to the experimental medium.
 
Data Analyses. 
 
Flow cytometry data were analyzed with
EXPO™ 32 Analysis software (Beckman Coulter). SigmaPlot 8.0
(Jandell Scientific) was used to create graphs, and GraphPad
Prism™ 4.0 (GraphPad Software) was used to perform Student’s 
 
t
 
test, Mann-Whitney test, or one-way analysis of variance with
the Tukey-Kramer posttest comparison of group means. Correla-
tion was analyzed by the Spearman correlation analysis. Signifi-
cance was accepted when P 
 
 
 
 0.05. To determine the optimum
cutoff value, the maximally selected 
 
 
 
2
 
 method of Miller and
Halpern was adapted. To determine the p-value associated with
the maximum 
 
 
 
2 statistics, we performed 2,000 bootstrap-like
simulations. For each simulation, a randomly selected expression
value was drawn from the set of observed expression values and
assigned to each of the observed responses (i.e., presence of
iNKTs). The corrected p-value was calculated as the proportion
Figure 1. Detection and enumeration of tumor-infiltrating iNKTs. (A)
iNKT cells ( 99% pure) were serially diluted with neuroblastoma cells
(LA-N-1 cell line) from 1:5 to 1:50,000, a iNKT/neuroblastoma cell ratio.
RT-PCR for V 24-J 18 RNA and flow cytometry for iNKT TCR anti-
gens were performed using cells from the same preparations. iNKT RNA
percentage (y axis) is calculated as iNKT RNA ng/500 ng (total sample)  
100 and plotted against iNKT cell frequency detected by flow cytometry (x
axis). Solid line is a linear regression, and dashed lines mark 95% confidence
interval, P   0.0001. (B) iNKT cell frequency in neuroblastoma tumors (n  
98) was calculated from detected iNKT RNA amount per 500 ng total sam-
ple RNA using the standard curve shown in A. (C) Frozen 6- m sections
were stained with Alexa Fluor® 488 anti-CD3 289-13801 (green), Cy-3
anti–V 24-J 18 6B11 (red) mAbs, and DAPI (blue). Digital image of micro-
scopic field of tumor tissue (magnification, 64) is one representative from five
analyzed iNKT  tumors (four to six fields per tumor) with green-circled T
cells and yellow (green   red)-circled iNKT among blue nucleated cells.Localization of Natural Killer T Cells in Neuroblastoma 1216
of the 2,000 simulated maximal  2 statistics that was larger than
the original maximal  2 test statistic.
Results
Detection and Enumeration of iNKTs Infiltrating Primary
Untreated Neuroblastomas.  Because the invariant V 24-
J 18 rearrangement specifically identifies iNKTs, we de-
signed a Taqman® probe/primer set to span and amplify a
V 24-J 18 sequence. The strict specificity and high sensi-
tivity of this set were established using  GalCer-reactive
iNKT and neuroblastoma cell lines as positive and negative
controls, respectively (unpublished data). To standardize
RT-PCR–based iNKT cell quantification, purified iNKTs
were serially diluted with neuroblastoma cells (LA-N-1 cell
line) and analyzed with RT-PCR and flow cytometry to
determine iNKT cell RNA concentration and frequency,
respectively (Fig. 1 A). iNKT RNA concentration linearly
correlated with iNKT cell frequency in the range from
0.01 to 25% (r   0.99, P   0.001), which provided a stan-
dard curve for subsequent analyses of iNKT cell frequency
in tumor specimens by RT-PCR.
RT-PCR analysis of 98 primary untreated stage 4 neuro-
blastomas revealed that 52 (53%) contained iNKTs. Their
frequency among all cells was calculated from specific iNKT
RNA concentration (Fig. 1 B), and it ranged from  0.01
(not detectable) to 0.52%. Tumors from all 19 patients who
were younger than 1 yr at diagnosis contained iNKTs,
whereas only 33 of 79 tumors (42%) from older patients
were iNKT . iNKT frequency was similarly distributed in
positive tumors regardless of the age of patients with a me-
dian of 0.06% and 25th and 75th percentiles of 0.015 and
0.14%. To confirm their presence in tumor tissues, we per-
formed three-color immunofluorescence microscopy on
five iNKT  and five iNKT  specimens (as determined by
RT-PCR) using DAPI for nuclear staining, anti-CD3 mAb
for T cells, and anti–V 24-J 18 CDR3 mAb 6B11 for
iNKTs. iNKT  specimens contained only T cells (green
fluorescence; not depicted), whereas iNKT  specimens
contained T cells and iNKTs (yellow fluorescence due to
green and red fluorescence colocalization; Fig. 1 C).
iNKT Infiltration and Chemokine Expression by Neuroblas-
toma Tumors and Cell Lines.  To examine whether iNKT
cell localization to neuroblastomas was associated with ex-
pression of chemokines in tumor tissues, we analyzed oligo-
nucleotide microarray expression data (U95Av2 arrays; Af-
fymetrix) for the 79 tumors diagnosed after 1 yr of age.
Among 43 chemokine genes evaluated, expression of CCL2
(r   0.52, P   0.001), CXCL12 (r   0.46, P   0.001),
CCL5 (r   0.43, P   0.001), and CCL21 (r   0.38, P  
0.005) correlated with iNKT infiltration into tumors (Fig. 2
A). In contrast, CD3  T cell infiltration correlated only
with expression of CCL21 (r   0.42, P   0.001).
Supernatants from eight neuroblastoma cell lines were an-
alyzed by ELISA for these four chemokines, and they se-
creted a range of CCL2 (0–21.6 ng/ml) and little CXCL12
( 0.1 ng/ml), but no detectable CCL5 or CCL21 (Table I).
Quantitative RT-PCR analysis of CCL2 expression by 17
neuroblastomas diagnosed after 1 yr revealed strong correla-
tion with microarray data for two out of three CCL2 probe
sets (r   0.98, P   0.001), and CCL2 expression by tumor
cells was detected by IHC in two representative tumors with
high levels of mRNA (Fig. 2 B). Comparison of iNKT 
versus iNKT  tumors diagnosed after 1 yr demonstrated sig-
nificantly greater expression of CCL2 in the former (iNKT :
median, 464 microarray FU; 25th and 75th percentiles, 158
and 532 FU; iNKT : median, 189 FU; 25th and 75th per-
centiles, 103 and 265 FU; P   0.001, Wilcoxon test). Im-
portantly, iNKTs could not be detected by RT-PCR in 21
neuroblastoma specimens with CCL2 gene expression  106
Figure 2. Chemokine expression in primary untreated neuroblastomas.
(A) Expression profiles were generated from 79 untreated stage 4 neuro-
blastomas from patients using Affymetrix U95Av2 oligonucleotide mi-
croarrays. All genes (black) are plotted according to their average level of
expression in tumors with undetectable (x axis) versus detectable (y axis)
V 24-J 18 RNA (iNKT TCR). Gene probe sets for 43 chemokines are
enlarged and labeled in red. Yellow dashed lines mark 95% confident interval.
Names of chemokine genes that positively correlate with iNKT RNA
expression are shown. (B) A tumor that expressed CCL2 mRNA was
immunostained with goat anti–human CCL2 followed by the Cell and
Tissue Staining Kit (R&D Systems). Tumor cells expressing CCL2 have
brown cytoplasm.Metelitsa et al. 1217
FU. For iNKT  tumors, the level of CCL2 correlated with
the extent of infiltration (r   0.4, P   0.018).
TEM of iNKTs to Supernatants of Neuroblastoma Cell Lines
Producing CCL2.  We examined whether supernatants
from neuroblastoma cell lines were chemoattractants for
iNKT cell lines. Fig. 3 A demonstrates that supernatants
from six out of eight tested neuroblastoma cell lines induced
iNKT cell TEM. Almost half of input iNKTs migrated to-
ward supernatants of CHLA-20 and SMS-KCN cell lines,
which secreted the highest levels of CCL2. In contrast,
iNKTs did not significantly migrate toward supernatant of
SMS-KCNR cells, which produced no CCL2 (Table I).
These experiments demonstrated a correlation between the
quantity of CCL2 in supernatants and the percentage of mi-
grating iNKTs (r   0.98, P   0.001). Next, we examined
the effect of neutralizing mAbs against the four candidate
chemokines (CCL2, CXCL12, CCL5, and CCL21) on
iNKT cell TEM toward supernatants from neuroblastoma cell
lines CHLA-20 and SMS-KCN (Fig. 3 B). Anti-CCL2 mAb
abrogated iNKT cell chemotaxis, whereas anti-CXCL12,
anti-CCL21, and anti-CCL5 mAbs had no effect.
iNKT Frequency, CCR2 Expression, and CCL2-dependent
TEM of Blood iNKTs from Children with Metastatic Neuroblas-
toma.  It has been reported recently that CCR2, which is
the only known functional receptor for CCL2, is expressed
on human iNKTs (15). To examine the effect of metastatic
disease (stage 4), we evaluated iNKTs from blood of neu-
roblastoma patients diagnosed after 1 yr with respect to fre-
quency (Fig. 4 A), expression of CCR2 (Fig. 4, B and C),
and TEM in response to CCL2 (Fig. 4 D). We found no
significant difference either in iNKT cell frequency or
CCR2 expression on the iNKT, NK, and T cells between
normal adults and neuroblastoma patients. Combining both
groups of subjects demonstrated that iNKTs more fre-
quently expressed CCR2 (median, 78%; range, 40–98%)
compared with NK cells (median, 5%; range, 1–11%) and
T cells (median, 21%; range, 10–37%; P   0.001, paired
signed rank test; Fig. 4 C). Migration of blood iNKTs from
neuroblastoma patients and normal adults in response to
CCL2 and CHLA-20 neuroblastoma cell line supernatant
also was not different, with both recombinant CCL2 and
supernatant from CHLA-20 cells inducing up to 55% TEM
of iNKTs from both patients and normal donors. As ex-
pected, migration in response to supernatant was specifi-
cally prevented by anti-CCL2 neutralizing mAb. In con-
trast to iNKTs, T and NK cells from patients and normal
adults migrated minimally (Fig. 4 D).
Patient Survival, iNKT Infiltration, MYCN Amplification/
Expression, and CCL2 Expression.  We evaluated iNKT
infiltration in relationship to clinical and molecular bio-
logic variables. Patients diagnosed after 1 yr of age with
metastases (stage 4) have high-risk disease, and the 79 stud-
ied patients received intensive chemotherapy or myeloab-
lative chemoradiotherapy (18). Their estimated survival 3
and 5 yr after diagnosis was 48 and 33%. Examination of
iNKT infiltration and survival demonstrated a trend to-
ward better outcome for those with iNKT-infiltrated tu-
mors, but the difference was not significant (P   0.32). Of
note, therapy received by all patients was immunosuppres-
sive with unknown effects on iNKT cell number and
function, which precludes a clear analysis of correlation
Table I. Chemokine Secretion by Neuroblastoma Cell Linesa
Cell line CCL2 CXCL12 CCL21 CCL5
pg/ml pg/ml pg/ml pg/ml
SKN-BE-2 65   6 27   1N D N D
SKN-BE-1 38   2 73   5N D N D
SMS-KCNR ND 62   2N D N D
SMS-KCN 5,367   8 89   3N D N D
SMS-KANR 47   3 56   2N D N D
SMS-KAN 72   4 103   8N DN D
CHLA-20 6,608   12 61   2N D N D
CHLA-15 56   5 65   1N D N D
aELISA was performed on supernatants collected from 106 cells after a
24-h incubation.
Figure 3. iNKT cell migration to neuroblastoma cell line supernatants.
(A) Medium alone or supernatants from neuroblastoma cell lines were
used to assess TEM of an iNKT cell line. Percentage of migrating cells is
indicated on the x axis. (B) Supernatants from neuroblastoma cell lines
mixed with 10  g/ml of neutralizing mAbs against indicated chemokines,
or mouse IgG1 isotype control mAbs were tested for chemotactic activity
using the same iNKT cell line and the TEM assay. Specific migration (x axis)
is shown as net migration after subtraction of migration to medium alone.
Results are mean   SD from duplicates of four experiments.Localization of Natural Killer T Cells in Neuroblastoma 1218
between only iNKT infiltration and survival. Patients di-
agnosed before 1 yr of age with stage 4 neuroblastoma
without MYCN gene amplification have intermediate-risk
disease (28). The 19 studied patients received much less
intensive chemotherapy, and all survived for  56 mo after
diagnosis. Analysis of outcome for all 98 patients in rela-
tionship to iNKT infiltration showed that survival was 64
and 35% at 5 yr for iNKT  and iNKT  tumors (P  
0.007; Fig. 5 A).
Genomic amplification of MYCN is associated with ag-
gressive tumor behavior (22). Survival for all 98 patients in
relationship to MYCN gene status was 65 and 30% for
MYCN nonamplified and amplified tumors (Fig. 5 B; P  
0.001). The 19 tumors diagnosed before 1 yr that were
studied were all nonamplified and all contained iNKTs.
Tumors diagnosed after 1 yr with MYCN amplification
and high-level expression surprisingly almost always lacked
iNKTs, whereas those in this group without amplification
accounted for nearly all with infiltration (P   0.001; Fig. 5
C). Furthermore, for patients diagnosed after 1 yr of age,
MYCN and CCL2 expression were inversely correlated
(Spearman correlation r    0.5, P   0.001; Fig. 5 D).
When MYCN and CCL2 RNA expression were catego-
rized according to optimal cut-points, iNKTs infiltrated
76% of MYCN-low/CCL2-high tumors but none of the
MYCN-high/CCL2-low tumors (P   0.001; Table II).
The association of iNKT infiltration also was tested with
MYCN and CCL2 jointly using a multivariate logistic re-
gression model containing the categorized expression of
MYCN and CCL2. In this model, the effects of both genes
on iNKT cell infiltration were independently significant
(P   0.01) and were additive but not synergistic. Thus,
MYCN-low/CCL2-high and MYCN-high/CCL2-low
Figure 4. CCR2 expression and migratory response of blood iNKTs
from neuroblastoma patients. (A) iNKT cell frequency in blood T cells of
normal donors (n   36) and neuroblastoma (NB) patients (n   8) was deter-
mined by three-color flow cytometry. (B) Representative flow cytometry
diagrams demonstrating iNKT frequency in patient PBLs (left) and CCR2
expression in this iNKT subset (right). (C) Mean   SD of CCR2 expres-
sion in indicated lymphocyte subpopulations from normal adults (n   10)
and neuroblastoma patients (n   6). (D) TEM of monocyte-depleted
peripheral blood lymphocytes from neuroblastoma patients (n   4) and
normal adults (n   4) was evaluated with indicated conditions. Results are
mean   SD from duplicates of four experiments.
Table II. Relationship between MYCN and CCL2 Expression 
and iNKT Cell Presence in 79 Neuroblastomas Diagnosed after 1 yr 
of Age
CCL2 expression levela
 134  134
MYCN   621 4/11b (36%) 25/33 (76%)
MYCN   621 0/22 (0%) 4/13 (31%)
aMeasured in fluorescence units.
bThe numerator is the number of tumors having iNKT infiltration, and
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were estimated to have 76 and 100% accuracy in predicting
iNKT presence and absence, respectively.
Discussion
This paper demonstrates infiltration of iNKTs into 53%
of primary untreated metastatic neuroblastomas and corre-
lation of infiltration with expression of CCL2, CCL5,
CCL21, and CXCL12. iNKT localization most likely was
primarily due to CCL2 because six out of eight neuroblas-
toma cell lines secreted CCL2, which was required and suf-
ficient for TEM of iNKTs in vitro. CCL2 expression was
inversely associated with MYCN gene amplification and
expression, and MYCN-high/CCL2-low expression accu-
rately predicted the absence of iNKTs in tumors. This is
the first correlation between oncogene activation, CCL2
expression, and iNKT cell infiltration. Together, our data
suggest that iNKTs migrate into neuroblastomas, particu-
larly those without MYCN amplification, in response to
CCL2.
The chemokine milieu in the tumor microenvironment
is likely to be a major determinant of infiltration and possi-
bly function of specific types of lymphoid and myeloid
cells. Although CCL2 alone mediated iNKT cell migration
to neuroblastoma cell line supernatants in vitro, tumors ex-
pressed three additional chemokines (CXCL12, CCL21,
and CCL5) that also correlated with iNKT cell infiltration.
These other chemokines could have contributed to local-
ization in vivo because iNKTs express receptors for them.
The receptors for all four chemokines are equally expressed
among functionally distinct CD4  and CD4  iNKT sub-
sets, and so it is not likely that a subset of iNKTs preferen-
tially infiltrated neuroblastomas (29–31). Chemokines also
may influence the type of immune response in a microen-
vironment by recruiting specific types of myeloid and lym-
phoid cells. Indeed, murine iNKTs recruited to lungs by
CCL2 after infection with Cryptococcus neoformans were im-
portant for development of Th1 immune responses because
both lung IFN-  production and specific delayed-type hy-
persensitivity were significantly greater in wild-type mice
than in V 14 NKT cell–deficient mice (32). Thus, the rep-
ertoire of chemokines expressed by tumors could deter-
mine localization of lymphocyte subsets and have a func-
tional effect on immune responses.
Our paper is the first to correlate iNKT cell infiltration
into a human tumor with CCL2 expression. Another inves-
tigation of 60 squamous cell carcinomas and adenocarcino-
mas of the lung demonstrated the presence of iNKTs with a
PCR assay for invariant V 24-J 18, but did not address
mechanisms of localization (13). Correlation of CCL2 ex-
pression and iNKT infiltration suggests that many types of
human tumors that express CCL2 also may contain iNKTs
(33). However, effects of CCL2 may be different depending
on chemokine level. For example, low expression of CCL2
after gene transfection into a nontumorigenic human mela-
noma cell line stimulated tumor formation in SCID mice,
whereas transfection that caused  100-fold higher expres-
sion was associated with large infiltration of inflammatory
cells (presumably monocytes) and tumor necrosis (34).
Expression of CD1d on APCs is required for iNKT cell
functional responses (35), and it has been demonstrated re-
cently that ganglioside GD3 derived from human melanoma
cells can be effectively cross-presented to murine iNKTs by
syngeneic APCs in a CD1d-dependent manner (36). Similar
to melanoma, neuroblastoma cells do not express CD1d
(20), but do produce a variety of gangliosides, including
Figure 5. Patient survival, iNKT infiltration, MYCN amplification/
expression, and CCL2 expression. (A) Survival for 98 patients whose tumors
did or did not have iNKT infiltration (P   0.007). (B) Survival for 98
patients whose tumors did or did not have MYCN amplification (P  
0.001). (C) MYCN expression and iNKT infiltration in primary neuro-
blastomas. MYCN RNA expression (y axis) was quantified by Affymetrix
U95Av2 oligonucleotide microarrays and V 24-J 18 RNA was detected
by Taqman RT-PCR in 79 untreated neuroblastomas. Tumors with detect-
able (NKT ) and undetectable (NKT ). iNKTs expressed 434.6   100.0
(n   33) and 1,378   139.5 (n   46) MYCN FU, respectively (Student’s
t test, P   0.001). (D) Correlation between MYCN and CCL2 expression.
MYCN (x axis) and CCL2 (y axis) RNA were quantified by Affymetrix
U95Av2 oligonucleotide microarrays in 79 untreated tumors. Regression
line demonstrates an inverse correlation between MYCN and CCL2 (r  
0.5, P   0.001, Spearman correlation analysis).Localization of Natural Killer T Cells in Neuroblastoma 1220
GD3 (37). Our oligonucleotide microarray analysis revealed
variable, but usually low level CD1d expression, which did
not correlate with iNKT infiltration. IHC of two represen-
tative tumors expressing CCL2 and containing iNKTs con-
firmed that tumor cells do not express CD1d, but showed
CD1d  cells, especially in stromal areas (unpublished data).
This indicates that iNKTs might function in the tumor mi-
croenvironment. Animal models suggest that in the absence
of exogenous stimulation, iNKTs may activate (6, 38) or
suppress antitumor immune responses (9, 10). However,
treatment with the iNKT cell ligand  GalCer (KRN7000),
which provides strong stimulation, unequivocally induces
potent antitumor responses in mice (4). Thus, understand-
ing mechanisms of localization and stimulation of iNKTs in
the tumor microenvironment is important for planning of
iNKT cell–mediated immunotherapy.
Disease and therapy could affect infiltration of iNKTs
into tumors. In this regard, we found no effect of metastatic
neuroblastoma at diagnosis (before therapy) on blood iNKT
cell frequency, CCR2 expression, or migratory response to
CCL2. Other studies of patients with cancer have evaluated
iNKT cell number in peripheral blood but have not investi-
gated their migration. One analysis of patients with ad-
vanced gastrointestinal cancers at diagnosis found normal
frequencies of iNKTs in blood, which is in agreement with
our observations (39). Two others of patients that had been
previously treated reported lower than normal iNKT cell
frequency in blood of patients with androgen-independent
metastatic prostate cancer (26) or with chemotherapy-resis-
tant solid tumors (40). These observations suggest that de-
veloping clinical immunotherapy with iNKTs will require
examination of effects of disease and therapies on circulating
iNKT cell number and function and, when possible, of tu-
mors for chemokine expression and iNKT cell infiltration.
Survival for patients whose tumors did or did not have
iNKT cell infiltration at diagnosis was significantly differ-
ent, but immunosuppressive chemotherapy or myeloabla-
tive chemoradiotherapy renders interpretation of this data
difficult. However, the survival curves for iNKT  versus
iNKT  groups were similar to those for MYCN amplified
versus nonamplified subgroups. This suggested a relation-
ship between iNKT infiltration and MYCN gene status.
Our analysis demonstrated for the first time an inverse cor-
relation between MYCN amplification and tumor infiltra-
tion by iNKTs that appears to be due, at least in part, to
decreased CCL2 production. MYCN amplification, which
causes protein overexpression, is independently associated
with aggressive tumor behavior in neuroblastoma (22), and
laboratory studies demonstrate that MYCN can have a di-
rect role in progression of neuroblastoma by activating or
repressing transcription of other genes (41, 42). Because
myc family oncoproteins, which include c-myc, N-myc,
and L-myc, have roles in the pathogenesis of many human
malignancies (43), our finding may have implications for
inflammatory and immune responses to several neoplasms.
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